Published finding — does the expert body still believe it?
Alirocumab subcutaneous injection every two weeks causes a higher rate of local injection-site reactions compared to placebo in post-ACS patients (3.8% vs. 2.1%).
TL;DR · AI-generated
Among patients who had a previous acute coronary syndrome and who were receiving high‐intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than amongThose who received placebo.
Author-implied confidence
90%
Status
DRAFT
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 1 snapshot
posterior drift
96% → 96% (0pp · 1 point)
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
· openalex W2899997727 · s2 3bd18f4d
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1519
Alirocumab treatment is associated with a numerically lower all-cause mortality rate compared to placebo in post-ACS patients on high-intensity statins (3.5% vs. 4.1%; HR 0.85; 95% CI 0.73–0.98).
0.1671
Alirocumab added to high-intensity statin therapy reduces the composite risk of coronary heart disease death, nonfatal MI, ischemic stroke, or unstable angina hospitalization compared to placebo in patients with recent acute coronary syndrome (HR 0.85; 95% CI 0.78–0.93).
0.1874
The absolute cardiovascular benefit of alirocumab over placebo is greater in post-ACS patients with a baseline LDL cholesterol of 100 mg/dL or higher compared to those with lower baseline LDL levels.
0.2083
The cardiovascular benefit of PCSK9 inhibition with alirocumab will be confirmed as a class effect applicable to other PCSK9 inhibitors in post-ACS patients on maximally tolerated statin therapy.
0.2163
In patients with atherosclerotic cardiovascular disease on statin therapy, evolocumab reduced LDL cholesterol by 59% at 48 weeks, from a median of 92 mg/dL to 30 mg/dL, compared with placebo.
0.2165
Evolocumab significantly reduced the key secondary composite endpoint of cardiovascular death, MI, or stroke (HR 0.80; 95% CI 0.73–0.88) compared with placebo in ASCVD patients receiving background statin therapy.